At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 110 target
Drug / intervention
IN10018 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Anti-tumor Efficacy of IN10018 Combined With Third-generation EGFR-TKI in Patients With Advanced EGFR Mutation-positive NSCLC
In Brief
A Phase 2 clinical trial evaluating IN10018 and Furmonertinib for NSCLC. Currently recruiting, targeting 110 participants across 1 site.
Detailed Summary
This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202420252026
Enrollment StartJul 2023
First PostedAug 2023
TodayJul 2026
Primary CompletionJul 2026
First PostedAug 16, 2023
Enrollment StartJul 13, 2023
Primary CompletionJul 31, 2026
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 2.9 years agoPrimary completion in 1 month
Interventions
IN10018drug
orally taken once daily
Furmonertinibdrug
orally taken once daily